CH649222A5 - Composizione farmaceutica per uso terapeutico, per uso diagnostico e quale integratore alimentare. - Google Patents
Composizione farmaceutica per uso terapeutico, per uso diagnostico e quale integratore alimentare. Download PDFInfo
- Publication number
- CH649222A5 CH649222A5 CH4268/81A CH426881A CH649222A5 CH 649222 A5 CH649222 A5 CH 649222A5 CH 4268/81 A CH4268/81 A CH 4268/81A CH 426881 A CH426881 A CH 426881A CH 649222 A5 CH649222 A5 CH 649222A5
- Authority
- CH
- Switzerland
- Prior art keywords
- arginine
- pharmaceutical composition
- lysine
- composition according
- diagnostic
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 230000001225 therapeutic effect Effects 0.000 title description 5
- 235000015872 dietary supplement Nutrition 0.000 title description 2
- 239000004475 Arginine Substances 0.000 claims description 30
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 30
- 239000004472 Lysine Substances 0.000 claims description 19
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- 229940088597 hormone Drugs 0.000 claims description 11
- 239000005556 hormone Substances 0.000 claims description 11
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 23
- 229960003646 lysine Drugs 0.000 description 22
- 239000000203 mixture Substances 0.000 description 16
- 235000018977 lysine Nutrition 0.000 description 14
- DQAKJEWZWDQURW-UHFFFAOYSA-N pyrrolidonecarboxylic acid Chemical compound OC(=O)N1CCCC1=O DQAKJEWZWDQURW-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 244000309715 mini pig Species 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 150000002231 fructose derivatives Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000934 organogenetic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT23101/80A IT1131854B (it) | 1980-06-30 | 1980-06-30 | Composizione farmaceutica per uso terapeutico,per uso diagnostico e quale integratore alimentare |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH649222A5 true CH649222A5 (it) | 1985-05-15 |
Family
ID=11203787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH4268/81A CH649222A5 (it) | 1980-06-30 | 1981-06-29 | Composizione farmaceutica per uso terapeutico, per uso diagnostico e quale integratore alimentare. |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS5714530A (enExample) |
| AU (1) | AU560450B2 (enExample) |
| CH (1) | CH649222A5 (enExample) |
| DE (1) | DE3115322A1 (enExample) |
| FR (1) | FR2485371A1 (enExample) |
| GB (1) | GB2078516B (enExample) |
| IT (1) | IT1131854B (enExample) |
| PT (1) | PT73286B (enExample) |
| ZA (1) | ZA814430B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3314079A1 (de) * | 1982-04-19 | 1983-12-22 | Papst Motoren Gmbh & Co Kg | Mehrwellenlaufwerk fuer kassetierte signaltraeger |
| DE3242501C1 (de) * | 1982-11-18 | 1984-03-29 | Degussa Ag, 6000 Frankfurt | Verwendung von waessrigen L-Lysin-Loesungen zur Supplementierung von Futtermitteln mit L-Lysin |
| FR2568124B1 (fr) * | 1984-07-24 | 1988-12-09 | Cortial | Medicament pour traiter les etats hypotrophiques par administrations d'aspartate d'arginine |
| AT393079B (de) * | 1989-03-06 | 1991-08-12 | Lubec Gert | Pharmazeutische verwendung von agmatin |
| US5077313A (en) * | 1988-11-25 | 1991-12-31 | Gert Lubec | Process for inhibiting pathological collagen cross-linking in diabetes patients |
| AT393080B (de) * | 1988-11-25 | 1991-08-12 | Lubec Gert | Pharmazeutische verwendung von arginin (salzen) |
| US6143786A (en) * | 1999-02-02 | 2000-11-07 | Novartis Nutrition Ag | Oral arginine and insulin secretion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6588M (enExample) * | 1967-10-11 | 1968-12-30 |
-
1980
- 1980-06-30 IT IT23101/80A patent/IT1131854B/it active
-
1981
- 1981-04-07 GB GB8110839A patent/GB2078516B/en not_active Expired
- 1981-04-15 DE DE19813115322 patent/DE3115322A1/de not_active Withdrawn
- 1981-04-17 JP JP5725381A patent/JPS5714530A/ja active Pending
- 1981-05-22 FR FR8110280A patent/FR2485371A1/fr active Granted
- 1981-06-29 AU AU72336/81A patent/AU560450B2/en not_active Ceased
- 1981-06-29 CH CH4268/81A patent/CH649222A5/it not_active IP Right Cessation
- 1981-06-29 PT PT73286A patent/PT73286B/pt not_active IP Right Cessation
- 1981-06-30 ZA ZA814430A patent/ZA814430B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT8023101A0 (it) | 1980-06-30 |
| AU560450B2 (en) | 1987-04-09 |
| PT73286A (en) | 1981-07-01 |
| GB2078516B (en) | 1985-02-27 |
| FR2485371B1 (enExample) | 1985-04-12 |
| FR2485371A1 (fr) | 1981-12-31 |
| GB2078516A (en) | 1982-01-13 |
| AU7233681A (en) | 1982-01-14 |
| ZA814430B (en) | 1982-09-29 |
| PT73286B (en) | 1982-07-22 |
| JPS5714530A (en) | 1982-01-25 |
| DE3115322A1 (de) | 1982-04-08 |
| IT1131854B (it) | 1986-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0742714B1 (en) | Liquid pharmaceutical compositions comprising thyroid hormones | |
| Gabay | Galactogogues: medications that induce lactation | |
| DEVLIN et al. | Captopril in human blood and breast milk | |
| US8722115B2 (en) | Methods for improving health in animals | |
| Kauppila et al. | Metoclopramide and breast feeding: efficacy and anterior pituitary responses of the mother and the child | |
| US9238024B2 (en) | Methods for improving health in canines | |
| HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
| CH649222A5 (it) | Composizione farmaceutica per uso terapeutico, per uso diagnostico e quale integratore alimentare. | |
| JPH10287560A (ja) | 医薬組成物 | |
| US20160000716A1 (en) | Method of treating vitamin b12 deficiency | |
| CN116059195A (zh) | 用于提高运动表现或预防或缓解疲劳的组合物和方法 | |
| CN102099033A (zh) | 用于治疗纤维肌痛症的药物组合物 | |
| Sinhamahapatra et al. | Effect of L-dopa on testosterone and luteinizing hormone production | |
| US9943520B2 (en) | Oral formulation and suspension of an oncology drug | |
| DE602004011275T2 (de) | Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit | |
| CA2086754C (en) | Treatment of human lactation failure | |
| WO2020093014A1 (en) | Drug compositions | |
| JP3096052B2 (ja) | 脂質代謝調節剤 | |
| Reimold | Chlorpropamide in the treatment of diabetes insipidus in children | |
| Borsa et al. | Pharmacokinetics of a slow-release preparation of ketoprofen lysine in man | |
| EP3345592A1 (en) | Enhanced stability ketorolac formulations and methods and devices for use with same | |
| KR20140145508A (ko) | 암브록솔 및 레보드로프로피진을 포함하는 안정성이 개선된 경구용 액상 제제 | |
| GB2199243A (en) | Pharmaceutical compositions comprising ornithine and arginine | |
| US6579905B1 (en) | Method for the prevention or treatment of hypomagnesemia in pediatric patients and in patients with G-tubes or NG-tubes | |
| WO1988004926A1 (en) | Nasal delivery of amino acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |